CenterBook Partners LP Has $2.87 Million Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

CenterBook Partners LP lowered its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 58.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,306,259 shares of the biopharmaceutical company’s stock after selling 1,806,326 shares during the quarter. CenterBook Partners LP owned approximately 0.66% of Esperion Therapeutics worth $2,874,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ESPR. Public Employees Retirement System of Ohio acquired a new stake in shares of Esperion Therapeutics during the third quarter worth approximately $606,000. Wellington Management Group LLP increased its holdings in Esperion Therapeutics by 66.8% during the 3rd quarter. Wellington Management Group LLP now owns 602,936 shares of the biopharmaceutical company’s stock valued at $995,000 after purchasing an additional 241,512 shares in the last quarter. Barclays PLC increased its holdings in Esperion Therapeutics by 99.6% during the 3rd quarter. Barclays PLC now owns 309,671 shares of the biopharmaceutical company’s stock valued at $510,000 after purchasing an additional 154,509 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in Esperion Therapeutics by 152.7% in the third quarter. BNP Paribas Financial Markets now owns 123,333 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 74,522 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Esperion Therapeutics by 1.0% during the third quarter. JPMorgan Chase & Co. now owns 2,069,117 shares of the biopharmaceutical company’s stock worth $3,414,000 after purchasing an additional 19,588 shares during the last quarter. 47.39% of the stock is currently owned by institutional investors and hedge funds.

Esperion Therapeutics Stock Down 0.9 %

ESPR stock opened at $1.05 on Thursday. Esperion Therapeutics, Inc. has a twelve month low of $0.97 and a twelve month high of $3.94. The company has a market cap of $207.74 million, a P/E ratio of -1.64 and a beta of 0.86. The business’s fifty day moving average is $1.62 and its 200-day moving average is $2.03.

Analyst Ratings Changes

A number of research analysts recently issued reports on ESPR shares. The Goldman Sachs Group started coverage on Esperion Therapeutics in a report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price target for the company. Needham & Company LLC reissued a “buy” rating and set a $5.00 price target on shares of Esperion Therapeutics in a research note on Tuesday. HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research report on Thursday, March 20th. Cantor Fitzgerald started coverage on Esperion Therapeutics in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 price objective on the stock. Finally, JMP Securities restated a “market outperform” rating and set a $4.00 target price (down previously from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Esperion Therapeutics presently has an average rating of “Hold” and an average target price of $6.58.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.